Interleukin-2 Therapy in Patients with HIV Infection

Abrams, D., Levy, Y., Losso, M. H., Babilker, A., Collins, G., Cooper, D. A., Darbyshire, J., Emery, S., Fox, L., Gordin, F., Lane, H. C., Lundgren, J. D., Mitsuyasu, R., Neaton, J. D., Phillips, A., Routy, J. P., Tambussi, G. and Wentworth, D. (2009) Interleukin-2 Therapy in Patients with HIV Infection. New England Journal of Medicine, 361 16: 1548-1559. doi:10.1056/NEJMoa0903175

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ632617_OA.pdf Full text (open access) application/pdf 473.98KB 0

Author Abrams, D.
Levy, Y.
Losso, M. H.
Babilker, A.
Collins, G.
Cooper, D. A.
Darbyshire, J.
Emery, S.
Fox, L.
Gordin, F.
Lane, H. C.
Lundgren, J. D.
Mitsuyasu, R.
Neaton, J. D.
Phillips, A.
Routy, J. P.
Tambussi, G.
Wentworth, D.
Title Interleukin-2 Therapy in Patients with HIV Infection
Journal name New England Journal of Medicine   Check publisher's open access policy
ISSN 0028-4793
Publication date 2009-10-01
Year available 2009
Sub-type Article (original research)
DOI 10.1056/NEJMoa0903175
Open Access Status File (Publisher version)
Volume 361
Issue 16
Start page 1548
End page 1559
Total pages 12
Place of publication Waltham, MA, United States
Publisher Massachusetts Medical Society
Language eng
Formatted abstract
Background: Used in combination with antiretroviral therapy, subcutaneous recombinant interleukin-2 raises CD4+ cell counts more than does antiretroviral therapy alone. The clinical implication of these increases is not known.

Methods: We conducted two trials: the Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy (SILCAAT) study and the Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT). In each, patients infected with the human immunodeficiency virus (HIV) who had CD4+ cell counts of either 50 to 299 per cubic millimeter (SILCAAT) or 300 or more per cubic millimeter (ESPRIT) were randomly assigned to receive interleukin-2 plus antiretroviral therapy or antiretroviral therapy alone. The interleukin-2 regimen consisted of cycles of 5 consecutive days each, administered at 8-week intervals. The SILCAAT study involved six cycles and a dose of 4.5 million IU of interleukin-2 twice daily; ESPRIT involved three cycles and a dose of 7.5 million IU twice daily. Additional cycles were recommended to maintain the CD4+ cell count above predefined target levels. The primary end point of both studies was opportunistic disease or death from any cause.

Results: In the SILCAAT study, 1695 patients (849 receiving interleukin-2 plus antiretroviral therapy and 846 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 202 cells per cubic millimeter were enrolled; in ESPRIT, 4111 patients (2071 receiving interleukin-2 plus antiretroviral therapy and 2040 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 457 cells per cubic millimeter were enrolled. Over a median follow-up period of 7 to 8 years, the CD4+ cell count was higher in the interleukin-2 group than in the group receiving antiretroviral therapy alone - by 53 and 159 cells per cubic millimeter, on average, in the SILCAAT study and ESPRIT, respectively. Hazard ratios for opportunistic disease or death from any cause with interleukin-2 plus antiretroviral therapy (vs. antiretroviral therapy alone) were 0.91 (95% confidence interval [CI], 0.70 to 1.18; P=0.47) in the SILCAAT study and 0.94 (95% CI, 0.75 to 1.16; P=0.55) in ESPRIT. The hazard ratios for death from any cause and for grade 4 clinical events were 1.06 (P=0.73) and 1.10 (P=0.35), respectively, in the SILCAAT study and 0.90 (P=0.42) and 1.23 (P=0.003), respectively, in ESPRIT.

Conclusions: Despite a substantial and sustained increase in the CD4+ cell count, as compared with antiretroviral therapy alone, interleukin-2 plus antiretroviral therapy yielded no clinical benefit in either study. ( numbers, NCT00004978 [ESPRIT] and NCT00013611 [SILCAAT study].)
Keyword Human-Immunodeficiency-Virus
Randomized Controlled-Trial
Cd4(+) Cell Counts
Subcutaneous Interleukin-2
Antiretroviral Therapy
Intravenous Interleukin-2
Q-Index Code C1
Q-Index Status Provisional Code
Grant ID U01 AI46957
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Faculty of Medicine
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 233 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 261 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 16 Jun 2017, 01:00:57 EST by Web Cron on behalf of Learning and Research Services (UQ Library)